Spotlight
Video

KEYNOTE-365 in mCRPC Results

obr has 860 videos Subscribe Here

Loading........
Description: William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of KEYNOTe-365, pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC).
Shared By : obr
Posted on : 07/01/19
Added : 2 months ago
Category : Prostate Cancer